Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta reports Q4 loss of $0.35, beating expected $0.41 loss. Restructuring and 34% workforce reduction aim to extend cash runway until 2029. Cash balance of $380.5M supports operations into 2029 for NKX019 trials. Analysts maintain buy ratings with price targets between $11 and $18. Positive price action with NKTX up 55.8% at $2.14.
View signal analysis